Literature DB >> 9671519

The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase.

L Meng1, N Sin, C M Crews.   

Abstract

Dynamic protein palmitoylation has been proposed to regulate GTP-binding proteins by controlling their membrane association and thus their access to key signaling proteins. While the palmitoyl protein thioesterase(s) responsible for depalmitoylation of plasma membrane-associated signaling proteins has (have) not been identified, the lysosomal palmitoyl protein thioesterase 1 (PPT1) has proven useful in in vitro studies of membrane localization requirements of GTP-binding proteins. We have previously reported the binding of the antiproliferative cyclic depsipeptide didemnin B to PPT1. To investigate the nature of this binding and its possible effects on PPT1 enzymatic activity, human PPT1 was expressed in an insect cell baculoviral system, and inhibition assays were performed using both [3H]palmitoyl Ha-Ras and myristoyl-CoA as PPT1 substrates. Didemnin B was shown to inhibit recombinant human PPT1 with a Ki of 92 nM. Kinetic analysis of this inhibition revealed that didemnin B inhibits PPT1 uncompetitively. Providing biochemical support for an uncompetitive mode of inhibition, in vitro binding studies of PPT1 and didemnin indicate that the natural product binds preferentially to the enzyme-substrate complex PPT1-palmitoyl-CoA. As the first described inhibitor of PPT1, didemnin B may prove to be a useful tool in the investigation of protein palmitoylation regulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671519     DOI: 10.1021/bi9804479

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

Authors:  A Mittelman; H G Chun; C Puccio; N Coombe; T Lansen; T Ahmed
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Total synthesis of Lys(3) tamandarin M: a potential affinity ligand.

Authors:  Kenneth M Lassen; Madeleine M Joullié
Journal:  Org Lett       Date:  2010-10-29       Impact factor: 6.005

Review 3.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

Review 4.  Advances in exploring the therapeutic potential of marine natural products.

Authors:  Xiao Liang; Danmeng Luo; Hendrik Luesch
Journal:  Pharmacol Res       Date:  2019-07-25       Impact factor: 7.658

5.  Selective N-Hydroxyhydantoin Carbamate Inhibitors of Mammalian Serine Hydrolases.

Authors:  Armand B Cognetta; Micah J Niphakis; Hyeon-Cheol Lee; Michael L Martini; Jonathan J Hulce; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2015-06-25

6.  Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B.

Authors:  Malia B Potts; Elizabeth A McMillan; Tracy I Rosales; Hyun Seok Kim; Yi-Hung Ou; Jason E Toombs; Rolf A Brekken; Mark D Minden; John B MacMillan; Michael A White
Journal:  Nat Chem Biol       Date:  2015-04-13       Impact factor: 15.040

7.  Consecutive interactions with HSP90 and eEF1A underlie a functional maturation and storage pathway of AID in the cytoplasm.

Authors:  Stephen P Methot; Ludivine C Litzler; Felipe Trajtenberg; Astrid Zahn; Francis Robert; Jerry Pelletier; Alejandro Buschiazzo; Brad G Magor; Javier M Di Noia
Journal:  J Exp Med       Date:  2015-03-30       Impact factor: 14.307

Review 8.  Natural Products Diversity of Marine Ascidians (Tunicates; Ascidiacea) and Successful Drugs in Clinical Development.

Authors:  Satheesh Kumar Palanisamy; N M Rajendran; Angela Marino
Journal:  Nat Prod Bioprospect       Date:  2017-01-17

9.  Treatment with didemnin B, an elongation factor 1A inhibitor, improves hepatic lipotoxicity in obese mice.

Authors:  Alexandra M Hetherington; Cynthia G Sawyez; Brian G Sutherland; Debra L Robson; Rigya Arya; Karen Kelly; René L Jacobs; Nica M Borradaile
Journal:  Physiol Rep       Date:  2016-09

10.  Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex.

Authors:  Jordan D Carelli; Steven G Sethofer; Geoffrey A Smith; Howard R Miller; Jillian L Simard; William C Merrick; Rishi K Jain; Nathan T Ross; Jack Taunton
Journal:  Elife       Date:  2015-12-10       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.